FTI Consulting Surges 16% on Earnings Beat as Shorts Hold Steady

FTI Consulting delivered one of its sharpest weekly moves in recent memory, rallying 16.3% to close at $182.84 after reporting quarterly results on October 29 that drove a single-day gain of 15.3%. The tension worth watching now is whether that move was enough to flush out short sellers or whether the bears simply held their ground through a result they had already anticipated.

The short positioning story is surprisingly stable given the scale of the price move. Short interest edged down just 1.6% over the week to 10.2% of free float, 3.07 million shares, suggesting no meaningful short covering accompanied the rally. The borrow market remains loose by any measure: availability is running at 479%, nearly five shares available for every one already borrowed, well above its 52-week low of 376%, and cost to borrow is a modest 0.58%. With that kind of lending supply, the move higher carried no technical squeeze dynamic, shorts could hold positions without pressure, and the data confirms they largely did. What is new is the pace at which availability tightened this week, dropping around 21% in seven days, still comfortable territory but the sharpest single-week tightening of the past month.

Options positioning shifted noticeably around the earnings date and tells a more nuanced story. The put/call ratio jumped to 0.75 this week, well above its 20-day average of 0.46, a z-score of 1.33, after spending the prior two weeks at or below 0.37 as the stock ran into results. That earlier low-PCR reading aligned with bullish sentiment ahead of earnings; the post-print shift toward puts suggests some investors are now hedging into the next leg or expressing doubt about whether the gap can hold. Notably, the PCR is nowhere near its 52-week high of 2.83, so this is elevated caution relative to recent norms, not extreme defensiveness.

The Street sits in an awkward position relative to where the stock is now trading. The consensus mean price target is $163.50, which is actually below Friday's close of $182.84. The most recent action came from Truist Securities on October 23, just before earnings, when analyst Tobey Sommer lowered his target from $180 to $158 while maintaining a Hold, a call that aged poorly within the week. Goldman Sachs last adjusted its Neutral rating in February 2025, cutting to $173. With the stock now above both targets, formal Street coverage is effectively running behind the tape. The ORTEX short score of 61.2 places FCN in the lower tier of the universe on short-side risk, and the factor scores reinforce the neutral tone: earnings yield ranks in the 61st percentile, EPS surprise at 54th, with short score rank in the bottom 8th percentile suggesting the data does not flag this as an extreme short setup in either direction.

One genuine standout from the alternative data is the buyback picture. ORTEX records show FCN logged its largest Q2 buyback spend on record going back to 2011, with $393 million deployed in the April quarter, also the highest quarterly reading since the series began in 2010. Retail attention has also picked up, with a Wikipedia views z-score of 1.53 against the stock's own 90-day history, measured as of October 22. Neither dataset has been shown to lead the company's reported figures in backtesting, so these are colour rather than signal, but the buyback activity does indicate management was actively buying shares at prices meaningfully above where the stock spent much of the prior twelve months.

Among the institutional register, T. Rowe Price added over 914,000 shares in the quarter to September 30, making it the most active large buyer recently at 8.3% of shares. JP Morgan Asset Management added 220,000 shares in the same period. On the 13D/G register, no activist holder is present. Kayne Anderson Rudnick remains the largest disclosed holder at around 11%, though its last ORTEX institutional filing reflects June 30 data and the 13G filing was from May 2025, so its current stake is as last disclosed. Among peers, Gartner slipped 3% on the week while EXPO gained 3.7% and EFX added 1.2%, meaning FCN's 16% move was a clear outlier driven by its own print rather than any sector tailwind.

With the next earnings date not until February 25, 2027, the immediate question is whether the stock can consolidate above the current analyst consensus, and whether short sellers, who held through the result, begin trimming at prices that now sit meaningfully above the Street's published targets.